| Let me tell you about a biotech company's new, patented painkilling prescription drug that could give you double-, maybe even triple-digit profits. Why? Because their breakthrough products could displace OxyContin, Vicodin, Lidoderm, Fentanyl and Opana ER. That's because this breakthrough drug has fewer side effects, unlike its competition. But--get this--it's also less addictive, unlike competitors' drugs. And it's getting a rare FDA fast track because it's so needed. With 334 million prescription pain drugs issued every year, doctors and people like you and I will demand the new, innovative drugs. This makes the company a disruptive factor in the pain-management sector. That's huge. This is an $8.3 billion industry that is about ready to be changed forever. What makes this a disruptive breakthrough is the fact that pain-management companies could lose major market share. And what does this potential disruption mean? Well.... 1. It's good for the company--billions could be made in potential sales.
2. And what I really like--it's good for patients.
3. And what my investors really like--it's good for early investors, who could enjoy double- or triple-digit profits. I'm Rick Currin, editor of the Currin BioTech Newsletter. And I know winners.
|||||
| Company | Ticker | Gain | Months Held | | Incyte | INCY | 405% | 48 | | Pharmacyclics, Inc. | PCYC | 2,320% | 48 | | Cepheid | CPHD | 178% | 53 | | Genomic Health | GHDX | 132% | 53 | | Cellceutix Corp. | CTIX | 108% | 24 | These profits enjoyed by my subscribers are a reflection of the fact that not once but 5 times I've received the coveted #1 ranking from the MarketWatch Hulbert Financial Digest rating service. Now I believe the company, Relmada (RLMD), could be one of my best picks ever. I've explained it all in my complimentary online report. More people visit the doctor's office for pain than anything else, including diabetes, heart trouble or cancer. This market is big and so is the stock potential to double or even triple your money. You can be one step ahead of the big institutional buyers if you act quickly. I've written a complimentary report here. You'll see my 7 reasons I think you can turn $5,000 into $10,000 or $15,000. I've alerted my subscribers to this rare opportunity. Plus, you can find out how to see all my biotech picks and recommendations in my newsletter, Currin BioTech. Just click here. Yours for new groundbreaking opportunities,
Rick Currin
Currin BioTech Newsletter Important Notice and Disclaimer: Currin BioTech is an independent paid circulation newsletter. This online report is a solicitation for subscriptions and a paid promotional advertisement of Relmada Therapeutics, Inc.(RLMD). Relmada Therapeutics, Inc. was chosen to be profiled after Currin BioTech completed due diligence on Relmada Therapeutics, Inc. Currin BioTech Newsletter expects to generate new subscriber revenue, the amount of which is unknown at this time, resulting from the distribution of this report. While receiving no direct compensation, and maintaining absolutely no obligation to provide any future views in support of the company highlighted, Currin BioTech Newsletter will receive indirect marketing support consistent with distribution of the report and will likely acquire new subscribers, the amount of which is not known at this time. Gramercy Strategic Partners LLC paid Nine hundred, sixty four thousand, three hundred and ninety one dollars fo! r the creation of various elements of this campaign in an effort to build investor awareness. This report does not provide an analysis of a company's financial position, operations or prospects and this is not to be construed as a recommendation by Gramercy Strategic partners LLC. or an offer to buy or sell any security, or investment advice. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. Do not base any investment decision based solely on information in this report. Although the information contained in this advertisement is believed to be reliable, Gramercy Strategic partners LLC. makes no warranties as to the accuracy of any of the contents herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due diligence, including consulting with a licensed, qualified investment professional. Further, readers are strongly urged t! o independently verify all statements made in this report. Relmada The rapeutics, Inc.(RLMD) financial position and all other information regarding Relmada Therapeutics, Inc.(RLMD) should be verified directly with Relmada Therapeutics, Inc.(RLMD). Audited financial statements and other relevant information about Relmada Therapeutics, Inc.(RLMD) can be found at the Security and Exchange Commission's website. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing all publicly available information, including the financial statements of the company. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1933, as amended, and section 21e of the Securities Act of 1934, as amended, including statements regarding growth of Relmada Therapeutics, Inc.(RLMD). In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look fo! rward in time, which include everything other than historical information, involve risks and uncertainties. All forward-looking statements are based upon current assumptions that are believed to be reasonable. In the event any such assumptions turn out to be incorrect, forward-looking statements based upon those assumptions will not be accurate. Currin BioTech presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. More information can be found at Relmada Therapeutics, Inc.(RLMD) website. |
0 comments:
Post a Comment